CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Micreos is developing targeted antibacterial products using endolysin technology to replace traditional antibiotics. This approach specifically targets harmful bacteria, offering a solution for skin conditions and infections while addressing the growing issue of antibiotic resistance.
According to the WHO, antibiotic resistance is one of humanity’s biggest health threats, claiming ~10 million extra deaths per year and US$100 trillion by 2050, unless alternatives to antibiotics are developed.
Micreos has developed the world’s first targeted antibacterial products, set to replace antibiotics.
With its endolysin technology, for the first time it is possible to kill only the unwanted bacteria, regardless of resistance.
Micreos’ endolysin technology was chosen as Europe’s most rel…
MICREOS HUMAN HEALTH BV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
